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ISSNObjective: LEDGF/p75, encoded by the PSIP1 gene, interacts with HIV-1 integrase and
targets HIV-1 integration into active genes. We investigated the influence of poly-
morphisms in PSIP1 on HIV-1 acquisition and disease progression in black South
Africans.
Methods: Integrase binding domain of LEDGF/p75 was sequenced in 126 participants.
Four haplotype tagging SNPs rs2277191, rs1033056, rs12339417 and rs10283923
referred to as SNP1, SNP2, SNP3 and SNP4, respectively, and one exonic SNP
rs61744944 (SNP5, Q472L) were genotyped in 195 HIV-1 seronegative, 52 primary
and 403 chronically infected individuals using TaqMan assays. LEDGF/p75 expression
was quantified by real-time RT-PCR. The impact of Q472L mutation on the interaction
with HIV_1 IN was measured by AlphaScreen.
Results: rs2277191 (SNP1) A was more frequent among seropositives (P¼0.06, Fish-
er’s exact test). Among individuals followed longitudinally SNP1A trended towards
association with higher likelihood of HIV-1 acquisition [relative hazard (RH)¼2.21,
P¼0.08; Cox model] and it was also associated with rapid disease progression
(RH¼5.98, P¼0.04; Cox model) in the recently infected (primary infection) cohort.
rs12339417 (SNP3)C was associated with slower decline of CD4þ T cells (P¼0.02) and
lower messenger RNA (mRNA) levels of LEDGF/p75 (P<0.01). Seroconverters had
higher preinfection mRNA levels of LEDGF/p75 (P<0.01) and these levels decreased
after HIV-1 infection (P¼0.02).
Conclusions: Genetic variants of PSIP1 may affect HIV-1 outcomes. Further studies are
needed to confirm the effect of genetic variation of PSIP1 on HIV-1 pathogenesis in
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Human immunodeficiency virus type 1 (HIV-1) requires
host cell factors for productive infection [1]. Lens
epithelium-derived growth factor p75 (LEDGF/p75)
also known as proprotein convertase 4 (PC4) or splicing
factor, arginine/serine-rich 1 (SFRS1)-interacting
protein 1 (PSIP1), is ubiquitously expressed in all tissues
and cell types (by convention, the gene and its protein are
referred to as PSIP1 and LEDGF/p75, respectively).
LEDGF/p75 is a member of the hepatoma-derived
growth factor (HDGF)-related protein family (HRP-
family) whose members are involved in chromosomal
replication, transcription and chromatin structure for-
mation [2–7]. LEDGF/p75 interacts with HIV-1
integrase through specific binding of the integrase-
binding domain (IBD) of LEDGF/p75 to the catalytic
core domain of integrase to tether HIV-1 to the
chromosome and target HIV-1 integration into active
genes [8–15]. Disruption of the interaction between
LEDGF/p75 and integrase, either by integrase mutations
or LEDGF/p75 knockdown, inhibits HIV-1 replication
[16–19], confirming the important role of host LEDGF/
p75 as an HIV-1 replication cofactor.
Association studies of the influence of human genetic
variation on HIV-1 replication may reveal the essential in-
vivo host factors that interact with HIV-1 and their
epidemiologic importance at the population level [20].
This approach has been used mostly in studies conducted
on populations from developed countries [20–23].
However, there are differences in allele frequencies among
potential disease-influencing gene variants between ethnic
groups and geographically separated populations [24].
Therefore, host genetic studies of HIV-1 infection need to
be extended to developing world populations heavily
burdened with HIV/AIDS. We investigated the influence
of genetic variation in PSIP1 on HIV-1 infection and
disease progression in black South Africans.Methods
Study participants
The Center for the AIDS Program of Research in South
Africa Acute Infection 002 (CAPRISA AI 002) [25,26]
and the Sinikithemba [27,28] cohorts were used for this
study. The CAPRISA AI 002 cohort is an ongoing
observational natural history study of HIV-1 subtype C
infection established in Durban, KwaZulu-Natal, South
Africa in 2004. HIV-negative women (n ¼ 245) at high
risk for HIV infection were enrolled into phase I of the
study. Participants in this cohort were screened monthly
for recent HIV-1 infection by two rapid HIV-1 antibody
tests (Abbott Laboratories, Tokyo, Japan) and Capillus
(Trinity Biotech, Jamestown, New York, USA). HIV-1
antibody-negative samples were tested for HIV-1 RNApyright © Lippincott Williams & Wilkins. Unauthoin batches of 10 plasma samples per pool using the
Ampliscreen v1.5 assay (Roche Diagnostics, Rotkreuz,
Switzerland), which has a detection limit of 10 copies/ml.
Samples that tested positive in pooled plasma were
individually tested by quantitative RNA (Amplicor v2.0,
Roche Diagnostics) and HIVenzyme immunoassay (BEP
2000; Dade Behring, Marburg, Germany) to identify
HIV-1 infection. CD4þ T-cell counts were determined
by a four-parameter FACSCalibur flow cytometer
(Becton Dickinson). Participants with acute HIV-1
infection were enrolled into phase II of the study on the
basis of a reactive HIV antibody test within 3 months of
previously negative results or positive HIV RNA PCR in
the absence of antibodies. Date of infection was estimated
by taking the midpoint between the last HIV antibody-
negative result and the first HIVantibody-positive result or
14 days before the first positive HIVRNA PCR assay result
for those identified as antibody-negative but HIV RNA-
positive. An additional 34 acutely infected participants
(who met the criteria for acute infection, as aforemen-
tioned) were recruited from other ongoing CAPRISA
cohorts. Participants in phase II were monitored weekly
for 3 weeks, fortnightly for 2 months then monthly for
9 months and quarterly thereafter.
The Sinikithemba cohort comprises 450 antiretroviral
naı̈ve, HIV-1 subtype C chronically infected adults
enrolled from McCord Hospital (Durban, South Africa)
from August 2003 to 2008 and followed longitudinally
[27,28]. Sociodemographic characteristics, plasma viral
load and CD4 cell count measurements were obtained at
baseline. CD4 cell counts and viral loads were measured
every 3 and 6 months, respectively, from enrollment. Viral
loads were determined using the automated Cobas
Amplicor HIV-1 Monitor test (version 1.5; Roche
Diagnostics). CD4þ T cells were enumerated using the
Multitest kit (CD4/CD3/CD8/CD45) on a FACSCa-
libur flow cytometer (Becton Dickinson).
Ethical approval for this study was obtained from
Biomedical Research Ethics Committee of the Univer-
sity of KwaZulu-Natal. All participants provided written
informed consent.
Identification of polymorphisms in the C
terminal region of PSIP1
Single-nucleotide polymorphisms (SNPs) in the C
terminal region of PSIP1 were screened in a panel of
83 seronegative and 43 seropositive black South African
women from the CAPRISA AI 002 cohort by
resequencing (Table 1).
Genotyping of single-nucleotide polymorphisms
in PSIP1 gene from the CAPRISA AI 002
participants
Four haplotype tagging (tag) SNPs rs2277191,
rs1033056, rs12339417 and rs10283923 in this manu-
script designated SNP1, SNP2, SNP3 and SNP4,rized reproduction of this article is prohibited.
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PCR primer sequence 50!30, TaqMan





LEDGF1 F: TGG GCT CAA AGC ATTA ATC C (958C, 10 min), 35 cycles of
(948C, 30 s; 608C , 30 s;
728C , 45 s) and (728C, 10 min)
Seq5 R: TCT GTG GCG TAT ACA CAG TG
Sequencing Seq1 F: GCC AGA TATGAT TTA ATC TAG (968C, 3 min), 25 cycles of
(968C, 15 s; 508C, 15 s;
608C, 2 s), (728C, 5 min)
Seq6 R: GTA GAC TTT TCC ATG ATT CCT GAC
Seq2 F: GCC TGT ATA TAG AAA TAC TGG
Seq5 R: TCT GTG GCG TAT ACA CAG TG
S9 F: CTT CAA AGG ATA CAT GC













PTZ1 F: GTC AAC CCC ACC GTG TTC TTC (958C, 6 s), (608C, 6 s) and
(728C, 10 s)
PTZ2 R: TTT CTG CTG TCT TTG GGA CCT TG
GAPDH NM_
002046
GAPDH1 F: AAG GTC GGA GTC AAC GGA TT (958C, 6 s), (608C, 6 s) and
(728C, 10 s)
GAPDH2 R: CTC CTG GAA GAT GGT GAT GG
F, forward primer; R, reverse primer; SNP, single-nucleotide polymorphism.respectively, available from NCBI dbSNP (http://www.
ncbi.nlm.nih.gov/SNP) and HapMap databases (http://
www.hapmap.org) selected by considering location,
spacing, and allele frequency of at least 10% and one
exonic SNP rs61744944 (Q472L) designated, SNP5 also
available from the aforementioned databases (Fig. 1a and
Table 1) were genotyped in 247 patient samples (195
seronegative and 52 seropositive individuals) from the
CAPRISA AI 002 cohort. The tag SNPs were chosen
because they are tag SNPs for PSIP1 in the Yoruba from
Nigeria (http://www.snp.cshl.org) and SNP5 based on the
preliminary analysis of the sequencing data that suggested
an association between SNP5 mutation and lower CD4 cell
count and higher viral load (P< 0.01 for both, data not
shown). Genotyping was performed by TaqMan SNP assay
as per manufacturer’s protocol (Applied Biosystems).
TaqMan assays were obtained from the Assay-by-Demand
service of Applied Biosystems (http://www.appliedbio-
systems.com). Eight negative water controls were included
in each run to rule out PCR contamination. Samples were
genotyped in duplicate and genotypes were accepted after
confirmation of no contamination or inconsistencies
between duplicates.
Genotyping of single-nucleotide polymorphisms
in PSIP1 gene from the Sinikithemba participants
PSIP1 SNPs associated with HIV-1 outcomes in the
CAPRISA AI 002 cohort were further analyzed in the
larger Sinikithemba cohort of 450 seropositive individ-Copyright © Lippincott Williams & Wilkins. Unautuals, in order to confirm the results obtained from the
CAPRISA AI 002. Genotyping assays were performed as
described above.
LEDGF/p75 mRNA expression analysis
Peripheral blood mononuclear cells (PBMCs) were
isolated from 57 seronegative and 38 seropositive
individuals from the CAPRISA AI 002 cohort. RNA
was extracted from 2  106 PBMCs immediately after
thawing using Trizol LS reagent (Invitrogen, Carlsbad,
California, USA) according to the manufacturer’s
protocol and the integrity of RNA was confirmed using
3-(N-morpholino) propanesulfonic acid (MOPS) gels.
RNA was reverse transcribed using the iScript comp-
lementary DNA (cDNA) synthesis kit (Bio-Rad).
LEDGF/p75 mRNA expression was quantified by
real-time PCR using SYBR Green Chemistry on a
Roche Lightcycler version 1.5 (Roche Diagnostics)
(Table 1).
Expression and purification of recombinant
proteins
His6-tagged HIV-1 integrase, 3xflag-tagged LEDGF/
p75, MBP-JPO2 and MBP-pogZ were purified for
AlphaScreen applications as described previously [29,30].
AlphaScreen
The AlphaScreen assay is a technique used to measure
protein–protein affinity interactions. To measure thehorized reproduction of this article is prohibited.
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Fig. 1. Locations of PSIP1 single-nucleotide polymorphisms on chromosome 9p22 and single-nucleotide polymorphisms
influence on disease outcome. (a) PSIP1 gene: coding exons are marked with solid blue boxes. Minor allele frequencies (MAFs)
of the single-nucleotide polymorphisms (SNPs) are shown for the CAPRISA and Sinikithemba (SK) cohorts. (b and c) Association of
individual SNPs with differential CD4þ T-cell counts and viral loads, respectively, during the acute infection phase (3months
post infection) of the CAPRISA 002 study cohort. (d and e) Association during the early chronic phase of infection (3–12 months) of
the CAPRISA 002 cohort. Rates of CD4 cell count decline stratified by genotypes for (f) SNP1, (g) SNP3 and (h) SNP5 for the
Sinikithemba seroprevalent cohort. Individuals homozygous for the major allele reference genotype are indicated in black,
heterozygous and homozygous for the minor allele are shown in red. MAF, minor allele frequencies for CAPRISA and Sinikithemba
cohorts are shown at the bottom of panel A. ND, not done. , An asterisk represents P values that remain significant after correction
for multiple comparison (Bonferroni), with a single asterisk representing P< 0.05 and double asterisks P<0.01.influence of SNP5T (Q472L) on the binding affinity
of LEDGF/p75 we performed AlphaScreen assay
according to the manufacturer’s protocol (Perkin Elmer,
Benelux). Reactions were performed in 25 ml volume in
384-well Optiwell microtiter plates (Perkin Elmer). The
reaction buffer contained 25 mmol/l Tris–HCl (pH 7.4),pyright © Lippincott Williams & Wilkins. Unautho150 mmol/l NaCl, 1 mmol/l MgCl2, 0.01% (v/v)
Tween-20 and 0.1% (w/v) bovine serum albumin.
Three-hundred mmol/l His6-tagged integrase was
incubated with 100 nmol/l flag-LEDGF/p75 for an hour
at 48C. Subsequently 5 ml of Ni-chelate-coated acceptor
beads and 5 ml antiflag donor beads were added to a finalrized reproduction of this article is prohibited.
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beads were incubated for 1 h at 308C. Exposure of the
reaction to direct light was avoided and the emission of
light from the acceptor beads was measured in the
EnVision plate reader (Perkin Elmer, Benelux) and
analyzed using the EnVision manager software. Assays
with JPO2 or pogZ, respectively, were essentially
performed as described previously [29,30].
Complemented cell lines
Complemented HeLaP4/CCR5 knockdown cells (A3
clone) were generated and grown as described earlier
[31]. Briefly, the Q472L mutation was introduced in
pLNC_LEDGF BC-Ires-Bsd and MLV-based vectors
were generated [31]. Following transduction, cells were
selected with 3 mg/ml blasticidin (Invitrogen, Merelbeke,
Belgium). Protein expression was verified by Western
blot analysis and immunocytochemistry (data not shown).
Virus strains
The molecular clone pNL4.3 was obtained through the
NIH AIDS Research and Reference Reagent Program.
Virus stock (HIVNL4.3) was produced as described earlier
[31].
HIV-1 breakthrough assay
Cells were seeded at 30 000 cells per well in a six-well dish
and infected as described earlier with minor modifi-
cations [19]. Briefly, cells were infected with 56 000 pg
p24 HIVNL4.3 in a total volume of 2 ml (MOI 0.01).
Twenty-four hours later, cells were washed twice with
1 PBS prior to addition of 4 ml of fresh medium. HIV
replication was monitored by sampling the culture
medium for p24 ELISA (HIV-1 p24 ELISA kit, Perkin
Elmer).
Quantitative PCR
Integrated proviral copies were quantified by real-time
quantitative PCR (Q-PCR) on genomic DNA using the
iQ5 Multicolor RT PCR detection system (BioRad,
Nazareth, Belgium). In order to allow quantification of
integrated proviral copies in HIV-1NL4.3 infected cells,
cells were subcultured at day 6 and grown under
zidovudine/ritonavir treatment for 10 days, 0.5 and
1.5 mmol/l, respectively, that is 25-fold IC50 as deter-
mined in MT4/MTT assay [32] to eliminate all
nonintegrated viral DNA. Genomic DNA was extracted
using the GenElute mammalian genomic DNA miniprep
kit (Sigma, Bornem, Belgium); for each reaction 100 ng
was used for Q-PCR. Integrated copies for HIV-1NL4.3
were quantified using a Gag-derived primer-probe set.
Each 25 ml reaction contained 12.5 ml 2 iQ Supermix
(BioRad), 40 nmol/l primer and 40 nmol/l probe.
RNaseP was used as house-keeping gene control
(TaqMan RNaseP control reagent; Applied Biosystems,
the Netherlands). All samples were run in quadruplet and
subjected to 3 min at 958C, 50 cycles of 958C for 10 s andCopyright © Lippincott Williams & Wilkins. Unaut558C for 30 s. Data were analyzed with iQ5 Optical
System software (BioRad, Nazareth, Belgium).
Statistical analysis
The difference in allele frequency distribution between
the HIV-1-positive and HIV-1-negative group was
determined by Fisher’s exact test (FET) for each SNP
to test the null hypothesis that allele frequencies were the
same in the two groups.
The effect of each SNP on HIV-1 viral load and CD4þT-
cell count was determined using a Generalized Estimating
Equation (GEE) model [33] taking into account
longitudinal measures for each participant. Viral loads
were log-transformed and the square root of CD4þT-cell
count was used to normalize their measurements.
Kaplan–Meier survival statistics and the Cox proportional
hazards model (Cox model) were used to assess the effect of
each SNP on time to HIV-1 infection after enrollment and
on the rate of progression to AIDS defined as CD4þT-cell
decline to less than 350 cells/ml (CD4 <350 cells/ml).
Decline in CD4 levels was determined and compared for
the group with one or two copies of the minor allele to a
reference group with two copies of the major frequency
allele (dominant genetic model), for each SNP. The
significance of genotypic associations and relative hazard
was determined by unadjusted Cox regression analysis for
the dominant genetic model.
LEDGF/p75 mRNA expression levels were compared
between seronegative and seropositive individuals by
performing dot plot graphical representation, nonpara-
metric statistical analysis, and correlation (Pearson).
Values were expressed as median values. Differences
between the two groups were evaluated using Dunn’s
multiple comparison test, whereas the Mann–Whitney
U-test was used for any two-group comparisons. The
software used for the analysis was SAS version 9.1.3 (SAS
Institute Inc., Cary, North Carolina, USA).Results
Study design and selection of patient samples
One hundred and ninety-five seronegative and 52
seropositive individuals from the CAPRISA AI 002
cohort and 403 seropositive individuals from the
Sinikithemba cohort were genotyped. Thirty-four samples
from the CAPRISA AI cohort and 48 samples from the
Sinikithemba cohort were excluded from all analysis due to
sample unavailability or poor quality genotype data.
Identification of Q472L as an exonic
polymorphism in the C-terminus of LEDGF/p75
The PSIP1 gene is 46.9 kb long and consists of 15 exons
(Fig. 1a). We sequenced part of the C-terminal region tohorized reproduction of this article is prohibited.
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Table 2. Association of PSIP1 single-nucleotide polymorphisms with HIV-1 acquisition in the CAPRISA AI 002 cohort, dominant model.
SNP, risk group n Genotype number (frequency)
22 and 12 versus 11
(reference group)M
RH (95% CI) P
SNP1, G!A GG AG AA
SN 183 158 (0.86) 22 (0.12) 3 (0.02)
SP 52 39 (0.75) 12 (0.23) 1 (0.01) 2.21 (0.92–5.28) 0.08
SNP2, G!C GG CG CC
SN 181 66 (0.36) 77 (0.43) 38 (0.21)
SP 52 20 (0.38) 23 (0.44) 9 (0.17) 0.99 (0.44–2.24) 0.98
SNP3, T!C TT CT CC
SN 172 86 (0.49) 64 (0.36) 22 (0.13)
SP 50 29 (0.58) 19 (0.38) 2 (0.04) 0.60 (0.26–1.37) 0.23
SNP4, A!G AA AG GG
SN 172 108 (0.63) 53 (0.31) 11 (0.06)
SP 48 31 (0.65) 16 (0.33) 1 (0.02) 0.85 (0.36–2.01) 0.71
SNP5, A!T AA AT TT
SN 184 162 (0.88) 21 (0.11) 1 (0.005)
SP 51 41 (0.80) 10 (0.20) 0 (0.00) 1.90 (0.71–5.09) 0.20
Kaplan–Meier survival statistics and the Cox proportional hazards model (Cox model) were used to assess the effect of each single-nucleotide
polymorphism (SNP) on time to HIV-1 acquisition after enrollment. P values uncorrected for multiple comparisons are shown. CI, confidence
interval; RH, relative hazard. M11 represents wild-type (homozygous) genotype, 12 heterozygous genotype, 22 mutant homozygous genotype.screen for SNPs in 83 seronegative and 43 seropositive
individuals from the CAPRISA AI 002 cohort. Fourteen
previously described SNPs (dbSNP, www.ncbi.nlm.nih.-
gov) were discovered (data not shown). Only one SNP
(rs61744944) was in the exon region and nonsynon-
ymous (Q472L).
Effect of PSIP1 single-nucleotide polymorphisms
on susceptibility to HIV-1 infection in the
CAPRISA AI cohort
The CAPRISA AI 002 cohort comprises high-risk
individuals who were initially identified as seronegative
and then followed longitudinally. This study design
allowed us to test whether genetic variation in PSIP1 was
associated with susceptibility to HIV-1 infection. The
minor allele frequencies (MAFs) of SNPs and haplotype
frequencies studied are shown (Fig. 1a). Kaplan–Meier
survival analysis of time to HIV-1 acquisition suggested a
trend of association between SNP1A and HIV-1
acquisition (relative hazard 2.21, 95% CI 0.92–5.28;
uncorrected P¼ 0.08, Cox model) (Table 2).
Association of PSIP1 single-nucleotide
polymorphisms with CD4R T-cell counts and
viral load in the CAPRISA AI 002 cohort
The approximate time of infection was known for
seropositive individuals in the CAPRISA AI 002 cohort
[26]. Since viral loads and CD4þ T-cell counts fluctuate
significantly during acute HIV-1 infection, we analyzed
the data in two intervals post infection, 0–3 months
(acute) and 3–12 months (early chronic), to detect
possible differences between genotypes during these
phases of infection.
A dominant model analysis using GEE showed significant
associations between SNP4G and lower CD4þ T-cellpyright © Lippincott Williams & Wilkins. Unauthocount (P<0.01, uncorrected) (Fig. 1b) and between
SNP5T and lower viral load (P¼ 0.02, uncorrected)
during acute phase of infection (Fig. 1c). SNP1A was
associated with lower CD4þ T-cell count (P < 0.01,
uncorrected) and SNP3C with higher CD4þ T-cell
count (P< 0.01, uncorrected) during early chronic phase
of infection (Fig. 1d). The minor allele of all SNPs, except
for SNP1, were associated with lower viral loads
(P< 0.05, uncorrected) during early chronic phase of
infection (Fig. 1e).
Effect of PSIP1 single-nucleotide polymorphisms
and haplotypes on CD4R T-cell decline in the
CAPRISA AI 002 cohort
We tested association of genetic variation with the rate of
CD4 decline to CD4 less than 350 in the CAPRISA
cohort. SNP1A was associated with rapid CD4þ T-cell
decline (P¼ 0.04 uncorrected, Cox model) (Table 3).
Haplotype 4 (HAP4) – the only haplotype carrying
SNP1A – was also trending towards association with
rapid CD4þ T-cell decline (relative hazard 2.46, 95% CI
0.87–6.93; P¼ 0.09) (Table 3). However, the effect of
SNP3C on CD4 decline could not be assessed in the
CAPRISA AI 002 cohort as there were only three
SNP3C participants whose CD4 cell count had dropped
to 350 cells/ml and below, at the time of this analysis.
Effect of PSIP1 single-nucleotide polymorphisms
on CD4R T-cell decline in the Sinikithemba
cohort
Interpretation of the data from the CAPRISA AI 002
cohort was complicated by small sample size of the cohort
and fluctuations in CD4þ T-cell counts and viral loads
that characterize acute and early chronic phases of HIV-1
infection. To further elucidate the role of PSIP1 genetic
variants in HIV-1 pathogenesis, we extended our analysisrized reproduction of this article is prohibited.
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Table 3. Effects of PSIP1 single-nucleotide polymorphisms on disease progression in the CAPRISA AI 002 cohort, dominant model.
Endpoint SNP number
SNPs on AIDS progression
Haplotype number
Haplotypes on AIDS progression
RH 95% CI P RH 95% CI P
CD4 <350 cells/ml SNP1 5.98 2.27–5.82 0.04 HAP1 1.84 0.55–6.12 0.77
CD4 <350 cells/ml SNP2 2.68 0.99–7.24 0.70 HAP2 0.84 0.19–3.77 0.21
CD4 <350 cells/ml SNP3 1.25 0.44–3.56 0.29 HAP3 0.00 0.00–0.00 0.99
CD4 <350 cells/ml SNP4 2.05 0.70–6.02 0.90 HAP4 5.41 1.92–5.24 0.09
CD5 <350 cells/ml SNP5 1.74 0.50–6.05 0.71 HAP5 1.58 0.36–7.49 0.66
Cox proportional hazards model (Cox model) was used to calculate the rate of CD4 decline to less that 350 cells/ml. P values uncorrected for
multiple comparisons are shown. CI, confidence interval; SNP, single-nucleotide polymorphism.to the larger Sinikithemba cohort from the same
geographical area. SNP2 and SNP4 were excluded from
this analysis because they were not associated with CD4þ
T-cell count during early chronic phase of infection in the
CAPRISA AI 002 cohort. Since the Sinikithemba cohort
is a seroprevalent cohort with unknown dates of
infection, we assessed the influence of each of SNPs
on disease progression by comparing the slopes of CD4þ
T-cell decline levels using the dominant model. SNP3C
was associated with delayed disease progression as
reflected by a slower rate of CD4þ T cells decline to
CD4 less than 350 (P¼ 0.02 uncorrected, Cox model)
(Fig. 1g).
LEDGF/p75 mRNA expression levels in the
CAPRISA AI 002 cohort
Quantitative RT-PCR on LEDGF/p75 mRNA levels
was performed in 57 seronegative and 38 seropositive
individuals. PBMCs obtained from seropositive individ-
uals had reduced LEDGF/p75 expression compared to
PBMCs obtained from seronegative individuals
(P¼ 0.02) (Fig. 2a). For 13 of seropositive individuals,
samples pre (baseline) and post-HIV-1 infection were
available for analysis. Baseline PBMCs from seroconver-
ters had higher LEDGF/p75 expression compared to
PBMCs from nonseroconverters (P< 0.01) (Fig. 2b).
SNP3C was significantly associated with reduced levels of
LEDGF/p75 (P< 0.01) (Fig. 2c) in both the seronegative
and seropositive groups and slower rate of CD4þ T-cell
decline (Fig. 1g) in the seropositive group.Copyright © Lippincott Williams & Wilkins. Unaut
Fig. 2. Expression of LEDGF/p75 mRNA in peripheral blood mono
LEDGF/p75 to GAPDH. (a) Expression of LEDGF/p75 mRNA in PBM
(b) Expression of LEDGF/p75 mRNA in PBMCs obtained seroconve
mRNA as modulated by different genotypes of SNP3. TT, wild type g
horizontal line in the middle of the points denotes the median vaFunctional analysis of Q472L LEDGF/p75
To determine the impact of the Q472L mutation on the
interaction with integrase – since this exonic mutation
was located adjacent to the IBD (amino acids 347–429) –
we measured LEDGF/p75-IN affinity in an AlphaScreen
assay and evaluated the effect of the Q472L mutation on
the interaction with JPO2 and pogZ, two cellular binding
partners of LEDGF/p75 [29,30]. Potent RNAi-mediated
knockdown of LEDGF/p75 also severely hampers HIV
replication affecting the integration step of the provirus
[19,34], a phenotype that is readily rescued upon re-
introduction of RNAi resistant LEDGF/p75 (LEDGF
BC) [31]. In a similar setting, we complemented potent
LEDGF/p75 knockdown cells with the Q472L variant
(LEDGF BC Q472L). Q472L did not alter the binding
affinity of LEDGF/p75 for integrase, JPO2 and pogZ and
complementation of LEDGF/p75-depleted cells with
mutant LEDGF/p75 (Q472L) rescued HIV-1 replication
to near wild-type levels (data not shown).Discussion
LEDGF/p75 promotes HIV-1 replication in vitro [9–11,
13,15,34,35]. In this study, we investigated the association
between genetic variation in PSIP1 and susceptibility to
HIV-1 infection and disease progression in two South
African cohorts. We found that SNP1A was associated
with higher likelihood of HIV-1 acquisition, lower CD4þhorized reproduction of this article is prohibited.
nuclear cells (PBMCs) represented as the normalized ratio of
Cs obtained from HIV-1-positive versus negative participants.
rters versus nonseroconverters. (c) Expression of LEDGF/p75
enotype of SNP3. CT, heterozygous genotype of SNP3. (–) The
lue.
Co
1718 AIDS 2011, Vol 25 No 14T-cell counts during the early chronic phase of infection
and rapid CD4þ T-cell depletion in CAPRISA 002 acute
infection cohort. SNP3C was associated with higher
CD4þ T-cell count and lower viral load during the early
chronic phase of infection in the CAPRISA AI 002
cohort.
The Sinikithemba cohort comprises chronically HIV-1-
infected individuals with unknown date of infection and
therefore we could examine the effect of SNPs on
trajectory of CD4þ T-cell decline over 6 years of follow-
up. SNP3C was significantly associated with delayed
disease progression as was reflected by a slower rate of
CD4þ T-cell decline in the Sinikithemba cohort. The
protective effect of SNP3C was consistent between the
two cohorts suggesting that SNP3C may be associated
with reduced HIV-1 replication.
Next, we investigated the association between PSIP1
genetic variation and expression levels of LEDGF/p75
and found that SNP3C was significantly associated with
lower levels of LEDGF/p75 which corroborates the
plausible role of SNP3C in reducing HIV-1 replication.
These findings suggest that SNP3C reduces the mRNA
levels of LEDGF/p75 thereby inhibiting HIV-1 replica-
tion, a finding that is consistent with in-vitro knockdown
studies [19,36]. Preinfection PBMCs from seroconverters
had significantly higher LEDGF/p75 mRNA levels
compared to nonseroconverters. HIV-1 infection
reduced LEDGF/p75 expression to lower levels com-
pared to uninfected individuals. These findings suggested
that high levels of LEDGF/p75 may increase the
likelihood of HIV-1 acquisition and the rate of disease
progression confirming that LEDGF/p75 is an important
host factor for productive HIV-1 infection [10]. On the
contrary, SNP1 associated with differential susceptibility
and early HIV-1 infection outcomes in the CAPRISA
acute infection cohort but not in the Sinikithemba
chronic infection cohort. This SNP was not associated
with differential LEDGF/p75 mRNA expression levels
and future studies will need to address other possible
contributing mechanisms.
Lastly, we analyzed the impact of the Q472L mutation on
LEDGF/p75–integrase interaction and plausible effects
on cellular binding factors of LEDGF/p75, JPO2 and
pogZ. Q472L did not alter the binding affinity of
LEDGF/p75 for integrase, JPO2 and pogZ and
complementation of LEDGF/p75-depleted cells with
mutant LEDGF/p75 (Q472L) rescued HIV-1 replication
to near wild-type levels. It is not inconceivable that this
mutation may affect other LEDGF/p75 functions such as
integration site targeting.
Conclusion
These findings demonstrate that genetic variation in
PSIP1 may influence susceptibility to HIV-1 infection
and disease progression, which provides in-vivo evidencepyright © Lippincott Williams & Wilkins. Unauthothat LEDGF/p75 is an important host cofactor for HIV-1
replication. However, due to small sample size and
heterogeneous nature of our cohorts, our findings should
be interpreted with caution and will need to be replicated
in additional studies.Acknowledgements
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